NASDAQ:IMPL Impel Pharmaceuticals (IMPL) Stock Forecast, Price & News $1.34 +0.24 (+21.64%) (As of 03:28 PM ET) Add Compare Share Share Today's Range$1.15▼$1.4450-Day Range$1.08▼$2.7652-Week Range$0.93▼$10.75Volume73,170 shsAverage Volume50,837 shsMarket Capitalization$31.83 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Impel Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,428.8% Upside$21.25 Price TargetShort InterestHealthy4.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.40) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector314th out of 1,006 stocksPharmaceutical Preparations Industry146th out of 492 stocks 3.3 Analyst's Opinion Consensus RatingImpel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.25, Impel Pharmaceuticals has a forecasted upside of 1,428.8% from its current price of $1.39.Amount of Analyst CoverageImpel Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.21% of the float of Impel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverImpel Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Impel Pharmaceuticals has recently decreased by 23.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImpel Pharmaceuticals does not currently pay a dividend.Dividend GrowthImpel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMPL. Previous Next 4.1 News and Social Media Coverage News SentimentImpel Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Impel Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for IMPL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Impel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Impel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.30% of the stock of Impel Pharmaceuticals is held by insiders.Percentage Held by Institutions63.92% of the stock of Impel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Impel Pharmaceuticals are expected to grow in the coming year, from ($3.40) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Impel Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Impel Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Impel Pharmaceuticals (NASDAQ:IMPL) StockImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.Read More Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Stock News HeadlinesMay 17, 2023 | uk.finance.yahoo.comImpel Pharmaceuticals Inc. (IMPL)May 13, 2023 | finance.yahoo.comImpel Pharmaceuticals First Quarter 2023 Earnings: Misses ExpectationsMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 12, 2023 | msn.comRecap: Impel Pharmaceuticals Q1 EarningsMay 12, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | msn.comEarnings Outlook For Impel PharmaceuticalsMay 11, 2023 | americanbankingnews.comImpel Pharmaceuticals (IMPL) Set to Announce Quarterly Earnings on FridayMay 10, 2023 | msn.comImpel Pharmaceuticals gets new CFOMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 10, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial OfficerMay 5, 2023 | finance.yahoo.comInvestors in Impel Pharmaceuticals (NASDAQ:IMPL) from a year ago are still down 67%, even after 26% gain this past weekMay 5, 2023 | finance.yahoo.comImpel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023April 26, 2023 | finance.yahoo.comImpel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine MedicationsApril 11, 2023 | finance.yahoo.comImpel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual MeetingApril 3, 2023 | americanbankingnews.comImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Short Interest UpdateMarch 30, 2023 | finance.yahoo.comImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results: Here's What Analysts Are Forecasting For This YearMarch 27, 2023 | finance.yahoo.comImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Q4 2022 Earnings Call TranscriptMarch 26, 2023 | finance.yahoo.comImpel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%March 24, 2023 | msn.comImpel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue EstimatesMarch 24, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 17, 2023 | finance.yahoo.comImpel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023March 3, 2023 | finance.yahoo.comImpel Pharmaceuticals to Participate in Upcoming Investor Conferences in MarchFebruary 24, 2023 | seekingalpha.comImpel Pharma says reducing headcount by 16%, eliminating pipeline programsFebruary 23, 2023 | msn.comWhy Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionFebruary 22, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial OpportunityFebruary 22, 2023 | finance.yahoo.comImpel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial OpportunityFebruary 14, 2023 | nasdaq.comOcular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Company Calendar Last Earnings3/24/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMPL CUSIPN/A CIK1445499 Webwww.Impelnp.com Phone206-568-1466FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.25 High Stock Price Forecast$40.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+979.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,310,000.00 Net Margins-716.73% Pretax Margin-716.73% Return on Equity-701.26% Return on Assets-115.51% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio1.97 Sales & Book Value Annual Sales$12.65 million Price / Sales2.61 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / Book-0.45Miscellaneous Outstanding Shares23,750,000Free Float22,253,000Market Cap$33.01 million OptionableNot Optionable Beta-0.26 Key ExecutivesMr. Adrian Adams (Age 71)Chairman & CEO Comp: $956.42kDr. John D. Hoekman Ph.D. (Age 41)Co-Founder and Chief Technology & Devel. Officer Dr. John H. Leaman M.D. (Age 49)Chief Financial & Bus. Officer Comp: $964.37kMr. Leonard S. Paolillo (Age 43)Chief Commercial Officer Comp: $496.7kMs. Jennifer L. BermanVP of MarketingMs. Patty BillingsleyVP of SalesMs. Sarah WilleVP of HRDr. Stephen Bevan Shrewsbury M.B. Ch.B. (Age 65)M.D., Chief Medical Officer Dr. Lynn C. Gold Ph.D. (Age 65)Sr. VP of Regulatory Mr. Scott Youmans (Age 55)Sr. VP of Technical Operations More ExecutivesKey CompetitorsVBI VaccinesNASDAQ:VBIVRegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMAcasti PharmaNASDAQ:ACSTMetacrineNASDAQ:MTCRView All CompetitorsInstitutional OwnershipState Street CorpSold 12,300 shares on 5/16/2023Ownership: 0.106%View All Institutional Transactions IMPL Stock - Frequently Asked Questions Should I buy or sell Impel Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMPL shares. View IMPL analyst ratings or view top-rated stocks. What is Impel Pharmaceuticals' stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month target prices for Impel Pharmaceuticals' stock. Their IMPL share price forecasts range from $5.00 to $40.00. On average, they predict the company's share price to reach $21.25 in the next twelve months. This suggests a possible upside of 1,428.8% from the stock's current price. View analysts price targets for IMPL or view top-rated stocks among Wall Street analysts. How have IMPL shares performed in 2023? Impel Pharmaceuticals' stock was trading at $3.75 at the beginning of the year. Since then, IMPL stock has decreased by 62.9% and is now trading at $1.39. View the best growth stocks for 2023 here. Are investors shorting Impel Pharmaceuticals? Impel Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 326,000 shares, a decline of 23.2% from the April 30th total of 424,400 shares. Based on an average trading volume of 64,100 shares, the days-to-cover ratio is presently 5.1 days. Currently, 4.2% of the shares of the stock are short sold. View Impel Pharmaceuticals' Short Interest. When is Impel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our IMPL earnings forecast. How were Impel Pharmaceuticals' earnings last quarter? Impel Pharmaceuticals Inc. (NASDAQ:IMPL) posted its quarterly earnings data on Friday, March, 24th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.07. The firm had revenue of $5.01 million for the quarter, compared to analysts' expectations of $4.06 million. Impel Pharmaceuticals had a negative trailing twelve-month return on equity of 701.26% and a negative net margin of 716.73%. When did Impel Pharmaceuticals IPO? (IMPL) raised $80 million in an initial public offering on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO. What is Impel Pharmaceuticals' stock symbol? Impel Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMPL." Who are Impel Pharmaceuticals' major shareholders? Impel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (0.11%). Insiders that own company stock include Adrian Adams, Global Strategic Fund I Venbio, Timothy S Nelson and Vivo Capital Viii, Llc. View institutional ownership trends. How do I buy shares of Impel Pharmaceuticals? Shares of IMPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Impel Pharmaceuticals' stock price today? One share of IMPL stock can currently be purchased for approximately $1.39. How much money does Impel Pharmaceuticals make? Impel Pharmaceuticals (NASDAQ:IMPL) has a market capitalization of $33.01 million and generates $12.65 million in revenue each year. The company earns $-106,310,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. How many employees does Impel Pharmaceuticals have? The company employs 129 workers across the globe. How can I contact Impel Pharmaceuticals? The official website for the company is www.Impelnp.com. The company can be reached via phone at 206-568-1466. This page (NASDAQ:IMPL) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.